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Objectives: Do prior percutaneous coronary interventions adversely affect the outcome of subsequent coronary
artery bypass grafting? We investigated this effect on a multicenter basis.
Methods: Eight cardiac surgical centers provided outcome data of 37,140 consecutive patients who underwent
isolated first-time coronary bypass grafting between January 2000 and December 2005. Twenty-two patient char-
acteristics and outcome variables were retrieved. Three groups of patients were analysed for in-hospital mortality
and in-hospital major adverse cardiac events: patients without a previous percutaneous coronary intervention,
with 1 previous intervention, and with 2 or more previous percutaneous coronary interventions before bypass
grafting. A total of 29,928 patients with complete information for prior percutaneous coronary intervention un-
derwent final analysis. Unadjusted univariate and risk-adjusted multivariate logistic regression analysis as well as
computed propensity score matching were performed, based on 14 major risk factors to correct for and minimize
selection bias.
Results: A total of 10.3% of patients had 1 previous percutaneous coronary intervention, and 3.7% of patients had 2
or more previous interventions. Risk-adjusted multivariate logistic regression analysis revealed a significant associ-
ation of 2 or more previous percutaneous coronary interventions with in-hospital mortality (odds ratio [OR], 2.0; con-
fidence interval [CI], 1.4–3.0; P¼ .0005) and major adverse cardiac events (OR, 1.5; CI, 1.2–1.9; P¼ .0013). After
propensity score matching, conditional logistic regression analysis confirmed the results of adjusted analysis. A his-
tory of 2 or more previous percutaneous coronary interventions was significantly associated with in-hospital mortality
(OR, 1.9; CI, 1.3–2.7; P ¼ .0016) and major adverse cardiac events (OR, 1.5; CI, 1.2–1.9; P ¼ .0019).
Conclusions: Multicenter analysis confirms that a history of multiple previous percutaneous coronary interven-
tions increases in-hospital mortality and the incidence of major adverse cardiac events after subsequent coronary
artery bypass grafting. Critical discussion of the treatment strategy in these patients is warranted.
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Worldwide, the number of coronary artery bypass grafting
(CABG) procedures performed per year reached a maximum
in the late 1990s and has declined since then by 20%.1 In
contrast, the number of percutaneous coronary interventions
(PCIs) performed per year keeps on growing exponentially
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CABG who have a history of previous PCI procedures rises.
Evidence from randomized trials3,4 and from large regis-
tries5-7 has proven that, concerning 3-vessel disease, CABG
is a more effective treatment than PCI, not only in terms of
freedom from recurrent angina and reintervention, but also
in terms of survival and freedom from major adverse cardiac
events (MACEs).
Just as important as the choice of therapy for patients with
coronary artery disease is the question of how one of the re-
spective therapies (CABG or PCI) may be influenced by the
Remagen, Koblenz University of Applied Science for the NRW (North Rhine-
Westphalia) CABG Study group, Koblenz, Germany.j
Drs Massoudy and Thielmann equally contributed to this work.
Received for publication June 24, 2008; revisions received Aug 20, 2008; accepted for
publication Sept 3, 2008.
Address for reprints: Parwis Massoudy, MD, Department of Thoracic and Cardiovas-
cular Surgery, West German Heart Center Essen, Hufelandstr. 55, 45147 Essen,
Germany (E-mail: parwis.massoudy@uk-essen.de).
J Thorac Cardiovasc Surg 2009;137:840-5
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.09.005gery c April 2009
Massoudy et al Acquired Cardiovascular Disease
A
C
DAbbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence intervals
COPD ¼ chronic obstructive pulmonary disease
LVEF ¼ left ventricular ejection fraction
MACE ¼ major adverse cardiac event
MI ¼ myocardial infarction
OR ¼ odds ratio
PCI ¼ percutaneous coronary intervention
other. CABG after prior PCI might not achieve the same
excellent results. Patients with initial percutaneous translu-
minal coronary angioplasty, who subsequently underwent
CABG, had a poorer long-term survival than those without
angioplasty.8 There is also evidence that PCI itself adversely
affects the outcome after repeated PCI.9 Recent single center
study data indicated that patients with 2 or more prior PCIs
have a significantly higher in-hospital mortality and MACE
rate when they subsequently undergo CABG.10 In the sub-
group of patients with multivessel disease and diabetes mel-
litus, 1 previous PCI procedure before subsequent CABG
was associated with an increase in-hospital mortality and
MACE rate.11 Moreover, recent data indicate that long-
term outcomes and quality of life are impaired after
CABG with prior PCI12 and that the rates of unstable angina
requiring hospitalization and the rates of repeated coronary
revascularization during follow-up are increased in CABG
patients with prior PCI.13
The present study was performed to compare early outcome
after CABG with and without prior PCI on a multicenter basis.
METHODS
Study Design
The study was a retrospective, multicenter, cohort study. Eight cardiac
surgical centers in North Rhine–Westphalia, the largest federal state in Ger-
many, participated. A total of 37,140 consecutive patients undergoing first
time isolated CABG between January 2000 and December 2005 were in-
cluded and assigned to groups as follows: group 1, no previous PCI; group
2, one single previous PCI; or group 3, multiple repeated (2) PCIs before
CABG. Single or multiple PCIs applies to episodes or sessions. This implies
that, in one session, more than one vessel may have been subjected to inter-
vention. Reoperative and concomitant cardiac surgical procedures were ex-
cluded. The study was approved by the institutional review boards of the
participating centers. All patients gave permission for the use of their med-
ical records for research purposes.
Data Collection
For each patient, 22 parameters were retrieved. Among them, 18 patients
and surgery characteristics (age, sex, obesity with a body mass index>30,
left main stem disease, left ventricular ejection fraction [LVEF], peripheral
vascular disease , chronic obstructive pulmonary disease [COPD], diabetes
mellitus, hypertension, ever smoking, hyperlipidemia, previous myocardial
infarction (MI), emergency, elective surgery, number of grafts, history of
PCI, number of prior PCI procedures, year of surgery), and four major event
categories (in-hospital death and in-hospital MACEs, the latter beingThe Journal of Thoracic and Cdefined as perioperative MI, low cardiac output syndrome, or cardiac death).
In most cases, PCI consisted of a combination of coronary stenting and
coronary balloon angioplasty. In a not further defined small number of
cases, percutaneous transluminal coronary angioplasty may have been the
only procedure preformed. In addition, other procedures such as coronary
atherectomy, coronary ablation therapy, and coronary brachytherapy may
have been performed. The dates of PCI procedures were not defined.
Outcome Measures and Definitions
The primary end point was in-hospital mortality after CABG. The sec-
ondary end point was the rate of MACEs. Previous MI was considered to
have occurred when one of the following criteria were present: (1) new per-
sistent ST-segment or T-wave changes, (2) the development of new Q
waves, (3) a creatine kinase level more than 3 times above the upper refer-
ence level, or (4) a cardiac troponin I level greater than 10.5 ng/mL. Low
cardiac output syndrome was assumed to exist in patients who had a cardiac
index less than 2.0 L $ min1 $ m2 or a systolic arterial pressure less than
90 mm Hg, despite high-dose inotropic support (intravenous dopamine
 8 mg $ kg1 $ min1, dobutamine  6 mg $ kg1 $ min1, epinephrine>
0.1 mg $ kg1 $ min1, or norepinephrine>0.1 mg $ kg1 $ min1). Death
was considered cardiac in origin if it was caused by previous MI, significant
cardiac arrhythmias, refractory low cardiac output syndrome, or if it was
otherwise unexplained.
TABLE 1. Baseline characteristics of the patients
Characteristic
No previous
PCI group
1 PCI
group
2 PCI
group
P
value
No. of patients 25,752 3,078 1,098
Age (y) 66.40  9.27 65.45  9.45 65.31  9.56 <.0001
Female sex (%) 26.96 26.26 26.25 .64
Obesity (%) 25.35 27.91 26.47 .0076
Left main stem
disease (%)
24.65 23.70 28.53 .0062
LVEF
<30% (%) 8.93 12.31 9.89
30–50% (%) 25.43 27.06 24.89 <.0001
>50% (%) 65.65 60.63 65.21
PVD (%) 15.21 16.98 20.43 <.0001
COPD (%) 9.86 8.03 10.97 .0019
Diabetes
mellitus (%)
27.55 29.51 28.90 .052
Hypertension (%) 83.75 88.07 90.36 <.0001
Ever smoking (%) 44.97 47.50 53.51 <.0001
Hyperlipidemia (%) 74.50 80.15 84.61 <.0001
Previous MI (%) 36.57 61.19 58.77 <.0001
Emergency (%) 6.12 7.67 7.47 .0011
No. grafts 2.82  0.90 2.55  0.84 2.59  0.90 <.0001
Year of operation
2000 (%) 5.35 1.98 4.55
2001 (%) 6.46 1.79 5.10
2002 (%) 24.96 24.50 20.13
2003 (%) 21.43 25.34 20.13 <.0001
2004 (%) 21.47 23.33 28.14
2005 (%) 20.33 23.07 21.95
PCI, Percutaneous coronary intervention; LVEF, left ventricular ejection fraction;
PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease;
MI, myocardial infarction. Data were presented as proportion or mean  SD. Year
of surgery denotes the percentage of patients of any one of the three groups, operated
on in the indicated year. Kruskal–Wallis test was used for continuous variables, c2 test
and Cochran–Armitage test were used for proportions. P value indicates maximum
significance level between any of the three groups.ardiovascular Surgery c Volume 137, Number 4 841
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DTABLE 2. Univariate and multivariate logistic regressions for in-hospital death
Univariate Multivariate (n ¼ 15,857)
OR (95% CI) P value OR (95% CI) P value
Age (y) 1.063 (1.053–1.072) <.0001 1.06 (1.045–1.074) <.0001
Female sex 1.37 (1.18–1.59) <.0001 1.10 (0.67–1.40) .43
Obesity 1.03 (0.87–1.21) .77 — —
Left main stem disease 1.17 (1.00–1.38) .051 0.94 (0.74–1.19) .61
LVEF
<30% 2.10 (1.63–2.72) <.0001 1.68 (1.18–2.38) .0037
30%–50% 1.83 (1.51–2.21) <.0001 1.31 (1.03–1.66) .026
>50% Reference value Reference value Reference value Reference value
PVD 1.79 (1.50–2.14) <.0001 1.58 (1.24–2.00) .0002
COPD 2.32 (1.94–2.78) <.0001 2.03 (1.57–2.62) <.0001
Diabetes mellitus 1.20 (1.03–1.40) .018 1.20 (0.96–1.49) .11
Hypertension 0.71 (0.60–0.85) .0002 0.91 (0.66–1.27) .58
Ever smoking 0.75 (0.65–0.87) .0001 1.20 (0.96–1.50) .10
Hyperlipidemia 0.59 (0.51–0.68) <.0001 0.98 (0.76–1.26) .85
Previous MI 1.39 (1.21–1.60) <.0001 1.36 (1.09–1.69) .0058
Emergency 5.03 (4.24–5.96) <.0001 4.23 (3.16–5.66) <.0001
No. grafts 0.99 (0.92–1.07) .79 0.91 (0.81–1.03) .14
Year of operation
2000 0.70 (0.48–1.03) .07 0.78 (0.49–1.25) .30
2001 0.72 (0.51–1.02) .07 0.78 (0.47–1.32) .36
2002 0.75 (0.61–0.93) .007 0.83 (0.61–1.12) .21
2003 1.05 (0.86–1.29) .62 1.58 (1.18–2.12) .002
2004 0.80 (0.65–0.99) .044 0.74 (0.53–1.05) .09
2005 Reference value Reference value Reference value Reference value
Group 1: no previous PCI Reference value Reference value Reference value Reference value
Group 2: single previous PCI 0.87 (0.67–1.11) .25 — —
Group 3: multiple previous PCIs 1.74 (1.29–2.33) .0003 2.02 (1.36–2.99) .0005
OR, Odds ratio; CI, confidence intervals; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease; COPD, chronic
obstructive pulmonary disease; MI, myocardial infarction.Perioperative Management
Surgical revascularization was performed either on cardiopulmonary by-
pass or off-pump. In all centers, the percentage of off-pump procedures was
less than 10%. For surgery with cardiopulmonary bypass, three centers used
intermittent crossclamping and five centers used the crossclamp technique
with cardioplegic arrest. The use of aprotinin was not uniform. Four centers
did not routinely use aprotinin. Four centers routinely used aprotinin, two
with 4.5 million KIU and two with half this dose in each patient. Aspirin
was continued until the day before surgery and resumed either on the day
of surgery or on postoperative day 1. If the patient did not have unstable an-
gina, preoperative medication with clopidogrel was discontinued at least 24
hours before surgery and resumed within 48 hours after surgery.
Statistical Analysis
Associations between PCI groups and prognostic factors were evaluated
by c2 or Kruskal–Wallis tests. Association between outcome (death and
MACE) and PCI was evaluated with the Cochran–Armitage test for trend.
Logistic regression analysis was performed to identify independent pre-
dictors for in-hospital death and MACE. Variables identified by univariate
regression analysis to have a probability value of .1 or less for association
with at least one study end point were added to the multivariate logistic re-
gression model. To control for selection bias as a result of nonrandom as-
signment to the three groups, we performed propensity score matching.14
The propensity scores were calculated separately by comparing between
group 1 versus group 2 and group 1 versus group 3, using logistic regression
with 14 risk factors (age, sex, obesity, left main stem disease, LVEF, periph-
eral vascular disease, COPD, diabetes, hypertension, ever smoking, hyper-842 The Journal of Thoracic and Cardiovascular Surlipidemia, previous MI, emergency, and number of grafts) and year of
surgery. For both comparisons, patients with similar propensity scores
were matched into 20 sets of equal size and conditional logistic regression
was used.15 Multiple adjusted odds ratios for group 3 versus group 1 con-
cerning in-hospital death and MACE were also calculated in subgroups de-
fined by certain risk factors. All statistical analyses were performed with the
SAS system, version 9.1 (SAS Institute Inc, Cary, NC).
RESULTS
The present analysis comprised 37,140 patients, and the
parameter no previous PCI/1 previous PCI procedure/2
previous procedures was documented in 29,928 (81%) of
these patients. Otherwise, the data sets were not complete
for peripheral arterial disease in 17.3% of patients and for
LVEF in 23.6% of patients. All other parameters were miss-
ing in less than 3%.
Preoperative characteristics of the patients are presented
in Table 1. Significant differences were present between
groups.
Of 29,928 patients, 794 (2.7%) died in-hospital and 2517
(8.4%) had MACEs. Of group 1 patients, 2.6% died in hos-
pital and 8.3% had MACEs. Of group 2 patients, 2.3% died
in-hospital and 8.6% had MACEs. Of group 3 patients, 4.5%
died in-hospital and 11.9% had MACEs. Cochran–Armitagegery c April 2009
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DTABLE 3. Univariate and multivariate logistic regressions for MACEs
Univariate Multivariable (n ¼ 15,805)
OR (95% CI) P value OR (95% CI) P value
Age (y) 1.024 (1.020–1.029) <.0001 1.024 (1.017–1.031) <.0001
Female sex 1.19 (1.09–1.30) .0002 1.18 (1.03–1.35) .01
Obesity 0.94 (0.85–1.03) .18 — —
Left main stem disease 1.21 (1.11–1.33) <.0001 1.03 (0.90–1.18) .65
LVEF
<30% 2.41 (2.09–2.78) <.0001 2.60 (2.15–3.15) <.0001
30%–50% 1.92 (1.73–2.13) <.0001 1.51 (1.32–1.72) <.0001
>50% Reference value Reference value Reference value Reference value
PVD 1.34 (1.20–1.50) <.0001 1.14 (0.98–1.32) .093
COPD 1.67 (1.48–1.88) <.0001 1.40 (1.19–1.66) <.0001
Diabetes mellitus 1.24 (1.14–1.36) <.0001 1.10 (0.97–1.24) .15
Hypertension 0.86 (0.77–0.96) .0074 0.88 (0.74–1.04) .13
Ever smoking 0.96 (0.88–1.04) .28 1.09 (0.96–1.23) .17
Hyperlipidemia 0.83 (0.76–0.91) <.0001 0.97 (0.84–1.12) .67
Previous MI 1.68 (1.55–1.82) <.0001 1.35 (1.20–1.53) <.0001
Emergency 4.34 (3.87–4.86) <.0001 3.61 (3.01–4.33) <.0001
No. grafts 1.04 (1.00–1.09) .082 1.08 (1.01–1.15) .030
Year of operation
2000 1.18 (0.98–1.41) .08 1.10 (0.89–1.37) .39
2001 0.90 (0.75–1.08) .25 0.87 (0.67–1.12) .27
2002 0.70 (0.62–0.79) <.0001 0.57 (0.49–0.68) <.0001
2003 0.77 (0.68–0.87) <.0001 0.92 (0.78–1.10) .36
2004 0.66 (0.58–0.75) <.0001 0.58 (0.48–1.70) <.0001
2005 Reference value Reference value Reference value Reference value
Group 1: no previous PCI Reference value Reference value Reference value Reference value
Group 2: single previous PCI 1.05 (0.92–1.20) .51 — —
Group 3: multiple previous PCI 1.50 (1.24–1.81) <.0001 1.51 (1.17–1.93) .0013
MACE, Major adverse cardiac event; OR, odds ratio; CI, confidence intervals; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; PVD, peripheral
vascular disease; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.test revealed a significant overall trend concerning in-hospi-
tal death (P ¼ .03) and MACE (P ¼ .0003) depending on
PCI groups.
Tables 2 and 3 show the results for univariate and multi-
variate logistic regression analysis. Besides other parame-
ters, a history of multiple prior PCIs was an independent
predictor for in-hospital death and for MACE.
After propensity score matching, the conditional logistic
regression model confirmed these results. A history of 2 or
more previous PCI procedures was significantly associated
with in-hospital mortality (odds ratio [OR], 1.9; confidence
interval [CI], 1.3–2.7; P ¼ .0016) and MACE (OR, 1.5; CI,
1.2–1.9; P ¼ .0019).
Adjusted ORs were also calculated in subgroups defined
by (1) with or without previous MI, (2) emergency yes/no,
(3) LVEF<50%/>50%, and (4) with or without COPD
(Table 4). The subgroups of LVEF <30% and LVEF
30%–50% were merged, because there were too few events
in the LVEF<30% subgroup to conduct a fully adjusted
analysis. In the subgroups of patients with or without previ-
ous MI, with or without COPD, with normal left ventricular
function (>50%), and in the subgroup of patients undergo-The Journal of Thoracic and Cing nonemergency surgery, 2 or more previous PCIs were
significantly associated with in-hospital death and with
MACE. In contrast, no association with either in-hospital
death or MACE was observed in the subgroup of patients
undergoing emergency surgery. In the subgroup of patients
with reduced LVEF (50%), 2 or more previous PCI proce-
dures were associated with in-hospital death but not with
MACE (Table 4).
DISCUSSION
There is now growing and cumulating evidence that
CABG after prior PCI is associated with a higher early mor-
tality and MACE rate,10,11 with impaired long-term outcome
and quality of life,12 and with more unstable angina requir-
ing hospitalization and repeated coronary revascularization
during follow-up.13 The present results obtained from al-
most 30,000 patients in a multicenter trial confirm these data.
Why do multiple prior PCI procedures lead to a worse out-
come after subsequent CABG? PCI procedures initiate
a sequence of inflammatory reactions,16 of poststenting
endothelial dysfunction,17 of periprocedural myocardial in-
jury,18 and of late poststenting structural changes.19 Theardiovascular Surgery c Volume 137, Number 4 843
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DTABLE 4. Adjusted odds ratios for in-hospital death and MACEs in patients with CABG after  2 previous PCIs versus CABG without previous
PCI from multiple logistic regression in subgroups
In-hospital death MACE
Subgroup (No. entering analysis) OR (95% CI) P value OR (95% CI) P value
No previous MI (n ¼ 9656) 2.02 (1.04–3.91) .038 1.55 (1.03–2.33) .037
Previous MI (n ¼ 6201) 2.02 (1.23–3.30) .0051 1.48 (1.08–2.03) .015
No emergency (n ¼ 15,085) 2.13 (1.40–3.25) .0004 1.57 (1.21–2.05) .0008
Emergency (n ¼ 772) 1.71 (0.53–5.47) .37 1.74 (0.79–3.81) .17
LVEF
>50% (n ¼ 10,708) 1.81 (1.04–3.12) .034 1.80 (1.32–2.47) .0002
50% (n ¼ 5149) 2.31 (1.31–4.08) .004 1.21 (0.80–1.81) .37
COPD
No (n ¼ 14,193) 1.68 (1.04–2.69) .033 1.33 (1.01–1.76) .045
Yes (n ¼ 1664) 3.28 (1.57–6.88) .0017 2.60 (1.47–4.60) .0010
MACE, Major adverse cardiac event; OR, odds ratio; CI, confidence intervals; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; MI, myocardial
infarction; LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulmonary disease.late structural changes may affect not only the stented area
itself but also the coronary artery section distal to the stent,
which would be the target area of a subsequent bypass graft
anastomosis.20 In fact, in a coronary artery that is covered
with stents, only distal sites remain for bypass graft anasto-
mosis, which may not offer adequate runoff so that a bypass
graft will have a poor prognosis.21 The assumption that
CABG can safely be performed in patients with coronary
stenting failure may not hold true and graft patency may
be adversely affected by prior coronary stenting. Coronary
side-branch obstruction or occlusion resulting from multiple
and overlapping stents may lead to compromised collateral
flow,22 inducing release of cardiac ischemic markers and
causing focal infarctions. Release of cardiac troponin I after
PCI has been reported for roughly 50% of patients with
stents.23 In these patients, the magnitude of irreversible
myocardial injury represented, on average, 5% of total left
ventricular mass.24 A possible reduction in left ventricular
function, associated herewith, could change the patient’s
risk profile, transferring him or her to a higher risk patient
subgroup, which may, by itself, explain the higher mortality
in CABG patients with a history of multiple previous PCI
procedures. This effect, however, did not apply to our
1098 patients with 2 or more PCIs before CABG, whose pre-
operative left ventricular function was not different from that
of the patients without prior PCI. Further investigation on
the number of PCIs and subsequent loss of left ventricular
function may clarify a possible correlation.
A history of multiple previous PCIs has now repeatedly
been shown to be associated with reduced survival and in-
creased MACE rate in CABG patients.10,11 We therefore
support critical reflection of the present referral policy,
which was repeatedly suggested in the recent past.25 How-
ever, from the current data we cannot exclude that, even after
multiple prior PCIs, further stenting may be superior to
CABG. For this high-risk patient subpopulation, further ev-
idence from a prospective study is warranted. Among other844 The Journal of Thoracic and Cardiovascular Suraspects, inadequate perioperative inhibition of platelet ag-
gregation may adversely influence the results. A discontinu-
ation of clopidogrel has been described to be the major
determinant of stent thrombosis within the first 6 months
after stent implantation.26
Limitations
The study has the widely known limitations of a retrospec-
tive and nonrandomized investigation. Even propensity
analyses cannot account for selection bias related to unmea-
sured characteristics. Although most of the modern era PCI
procedures are coronary stents in combination with balloon
angioplasty, we cannot exclude that, in some cases, balloon
angioplasty or other procedures such as coronary atherec-
tomy were the only procedures performed. Because of data
base limitations, we could report neither the vessel territories
targeted with PCI nor the time intervals between PCI and
CABG procedures. The primary and secondary end points
of the present study were in-hospital mortality and in-hospi-
tal MACE. Again, the data bases did not allow us to report
on perioperative neurologic complications and long-term
outcomes. Furthermore, early mortality, better defined as
30-, 60-, or 90-day all-cause mortality,27 could only be fol-
lowed until discharge from the surgical department.
The specific value of the present study is its nature of
a ‘‘real life’’ patient investigation. All first-time CABG pa-
tients, irrespective of comorbidities, were included in the
study. Because of the multicenter orientation, the surgical
strategies, perioperative anticoagulation therapy, and other
factors were not uniform. This also applies to the use of apro-
tinin, which is suspected to be associated with increased
complications in cardiac surgical patients.28 On the other
hand, the severe limitations of randomized studies compar-
ing CABG and PCI were recently reported. Because of in-
clusion and exclusion criteria, only 5% of the total eligible
patient population are generally included in such studies,
omitting the sicker and more comorbid patients.29gery c April 2009
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DAnother caveat of the present study is the rapid develop-
ment of the state of the art treatment in both CABG and PCI.
In CABG, the number of off-pump procedures and of total
arterial revascularization increases. In PCI, new technology
such as self-resorbing stents has lately been introduced into
clinical practice.30
CONCLUSION
In this multicenter study, we observed a significantly
higher in-hospital mortality and MACE rate in CABG pa-
tients with 2 or more prior PCIs compared with no prior
PCIs. The mechanism is multifactorial and is possibly trig-
gered by an inflammatory reaction, repetitive myocardial is-
chemia, and endothelial dysfunction. Single and multicenter
studies investigating ‘‘real-life’’ patients have now gener-
ated strong evidence that multiple previous PCI procedures
put patients at higher risk during subsequent CABG. A crit-
ical reflection of the revascularization strategy for this high-
risk patient cohort is warranted.
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